Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Baymedica
Deal Size : Inapplicable
Deal Type : Inapplicable
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
Details :
Product Name : d9-THCV
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Baymedica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Radicle Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : d9-THCV
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Radicle Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Incannex to Acquire APIRx Pharmaceuticals USA, LLC
Details : A focus of the combined APIRx and Incannex group will be the ongoing development of APIRx's CheWell, CanQuit and CanQuit-O cannabinoid combination MCGs to treat cannabis addiction, nicotine addiction and opioid addiction.
Product Name : CheWell
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 24, 2022
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition